New drug application for RTK inhibitor for the treatment of renal cell carcinoma

Recently, Allarity Therapeutics announced that it has submitted a New Drug Application (NDA) to the US FDA to seek approval of the receptor tyrosine kinase (RTK) inhibitor dovitinib for the third-line treatment of renal cell carcinoma (RCC)

Dovitinib is a small molecule RTK inhibitor that has previously shown clinical activity in many cancer indications, including RCC, gastrointestinal stromal tumor (GIST), endometrial cancer, metastatic breast cancer and hepatocellular carcinoma ( HCC)

And Allarity's DRP companion diagnostic technology platform, by analyzing the tumor cell RNA of more than 3000 patient tumors and the gene expression data of multiple drugs, is expected to predict whether specific cancer patients are likely to be treated with dovitinib in addition to a wide range of anticancer drugs.

Dovitinib-DRP companion diagnosis is expected to be used to identify patients with advanced RCC who are likely to have a high response to dovitinib through the gene expression characteristics of their tumors

Reference materials:

[1] Allarity Therapeutics Submits New Drug Application (NDA) to the US FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC).

(The original text has been deleted)